Yttrium-90

Yttrium-90. It is a radioactive isotope of the element yttrium with significant applications in the field of nuclear medicine and industry. Produced primarily from the decay of strontium-90, a fission product, it is a pure, high-energy beta particle emitter. Its physical and nuclear properties make it exceptionally useful for targeted radiation therapies and as a tracer in various industrial processes.

Properties

Yttrium-90 decays with a half-life of approximately 64 hours to stable zirconium-90. It emits beta particles with a maximum energy of 2.28 MeV and an average energy of 0.94 MeV, which corresponds to a maximum tissue penetration of about 11 mm and an average of 2.5 mm. This isotope has no accompanying gamma ray emission, which simplifies radiation protection measures. The decay scheme and the chemical nature of the yttrium cation allow it to form stable chelates with various bifunctional chelators, a critical property for its medical use.

Production

The primary source of yttrium-90 is the decay of its parent nuclide, strontium-90, which is a long-lived fission product obtained from spent nuclear fuel from reactors like those at Sellafield or Mayak. A strontium-90/yttrium-90 generator system, analogous to the technetium-99m generator used in hospitals, allows for the milking of the pure daughter isotope. Yttrium-90 can also be produced directly by neutron irradiation of stable yttrium-89 in nuclear reactors such as the High Flux Isotope Reactor at Oak Ridge National Laboratory. The direct production route is essential for creating carrier-free material used in advanced pharmaceutical preparations.

Medical applications

In nuclear medicine, yttrium-90 is a cornerstone of targeted radionuclide therapy. It is most famously used in radioembolization for treating unresectable hepatocellular carcinoma and metastases to the liver, where microspheres are injected into the hepatic artery. The isotope is also conjugated to monoclonal antibodies like ibritumomab tiuxetan in the treatment of relapsed non-Hodgkin lymphoma, a regimen approved by the U.S. Food and Drug Administration. Furthermore, it is used in radiosynovectomy for conditions like rheumatoid arthritis to ablate inflamed synovial tissue. Research continues at institutions like the National Institutes of Health into its use with novel peptides for treating neuroendocrine tumors.

Industrial and research applications

Beyond medicine, yttrium-90 serves as a robust radioactive tracer in industrial and research settings. In the petroleum industry, it is used to study fluid dynamics and monitor the efficiency of fracturing processes in oil wells. Researchers at facilities like CERN and the Joint Institute for Nuclear Research utilize it in studies of nuclear structure and decay processes. Its pure beta emission makes it suitable for thickness gauging in manufacturing processes for thin materials like paper and metal foils. It has also been investigated as a component in radioisotope thermoelectric generators for specialized applications.

Safety and handling

Handling yttrium-90 requires strict adherence to ALARA principles due to its high-energy beta radiation. Primary hazards include external exposure to skin and eyes, and potential internal contamination, which can lead to significant localized tissue damage. Shielding is typically accomplished using low-atomic-number materials like plexiglass or Lucite. Personnel monitoring involves the use of thermoluminescent dosimeters and routine surveys with Geiger-Müller counters. All work is conducted under the regulatory frameworks of agencies such as the Nuclear Regulatory Commission in the United States. Waste disposal follows protocols for intermediate-level radioactive waste, often requiring decay storage for ten half-lives before disposal as low-level waste.

Category:Yttrium Category:Medical isotopes Category:Industrial isotopes